CL2008001238A1 - Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi - Google Patents
Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un piInfo
- Publication number
- CL2008001238A1 CL2008001238A1 CL2008001238A CL2008001238A CL2008001238A1 CL 2008001238 A1 CL2008001238 A1 CL 2008001238A1 CL 2008001238 A CL2008001238 A CL 2008001238A CL 2008001238 A CL2008001238 A CL 2008001238A CL 2008001238 A1 CL2008001238 A1 CL 2008001238A1
- Authority
- CL
- Chile
- Prior art keywords
- mediated
- crig
- complement
- inhibit
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Antagonista del receptor crig; ácido nucleico que lo codifica; composición farmacéutica que lo comprende; y método para inhibir la entrada celular dependiente del complemento mediada por crig de un patógeno intracelular; y método para depurar un patógeno intracelular de la circulación de un mamífero.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91534007P | 2007-05-01 | 2007-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001238A1 true CL2008001238A1 (es) | 2008-11-07 |
Family
ID=39645433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001238A CL2008001238A1 (es) | 2007-05-01 | 2008-04-30 | Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090162356A1 (es) |
EP (1) | EP2152749A1 (es) |
JP (1) | JP2010526076A (es) |
KR (1) | KR20100018523A (es) |
CN (1) | CN101675078A (es) |
AR (1) | AR066375A1 (es) |
AU (1) | AU2008247958A1 (es) |
BR (1) | BRPI0810926A2 (es) |
CA (1) | CA2682835A1 (es) |
CL (1) | CL2008001238A1 (es) |
IL (1) | IL201165A0 (es) |
MX (1) | MX2009011407A (es) |
PE (1) | PE20090239A1 (es) |
RU (1) | RU2009144280A (es) |
WO (1) | WO2008137338A1 (es) |
ZA (1) | ZA200906812B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
JP5836800B2 (ja) * | 2008-05-06 | 2015-12-24 | ジェネンテック, インコーポレイテッド | 親和性成熟CRIg変異体 |
US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
CN104231085B (zh) * | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
CN105924515B (zh) * | 2016-04-25 | 2019-06-14 | 中国人民解放军第三军医大学 | 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
WO2019005817A2 (en) | 2017-06-26 | 2019-01-03 | Bio-Techne Corporation | HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME |
CN113423728B (zh) * | 2018-09-28 | 2024-03-01 | 优特力克斯有限公司 | 抗人vsig4抗体及其应用 |
US20220233756A1 (en) * | 2019-05-17 | 2022-07-28 | George A. Herzlinger | Methods and systems for treating microbial disease |
US20220306736A1 (en) * | 2019-09-04 | 2022-09-29 | Y-Biologics Inc. | Anti-vsig4 antibody or antigen binding fragment and uses thereof |
KR20230156727A (ko) | 2021-03-03 | 2023-11-14 | 피에르 파브르 메디카먼트 | 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
-
2008
- 2008-04-25 CA CA002682835A patent/CA2682835A1/en not_active Abandoned
- 2008-04-25 WO PCT/US2008/061513 patent/WO2008137338A1/en active Application Filing
- 2008-04-25 KR KR1020097024920A patent/KR20100018523A/ko not_active Application Discontinuation
- 2008-04-25 EP EP08769166A patent/EP2152749A1/en not_active Withdrawn
- 2008-04-25 AU AU2008247958A patent/AU2008247958A1/en not_active Abandoned
- 2008-04-25 CN CN200880014866A patent/CN101675078A/zh active Pending
- 2008-04-25 RU RU2009144280/10A patent/RU2009144280A/ru not_active Application Discontinuation
- 2008-04-25 JP JP2010506507A patent/JP2010526076A/ja active Pending
- 2008-04-25 MX MX2009011407A patent/MX2009011407A/es active IP Right Grant
- 2008-04-25 BR BRPI0810926-5A2A patent/BRPI0810926A2/pt not_active IP Right Cessation
- 2008-04-25 US US12/150,220 patent/US20090162356A1/en not_active Abandoned
- 2008-04-30 AR ARP080101847A patent/AR066375A1/es not_active Application Discontinuation
- 2008-04-30 PE PE2008000774A patent/PE20090239A1/es not_active Application Discontinuation
- 2008-04-30 CL CL2008001238A patent/CL2008001238A1/es unknown
-
2009
- 2009-09-24 IL IL201165A patent/IL201165A0/en unknown
- 2009-09-30 ZA ZA2009/06812A patent/ZA200906812B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2682835A1 (en) | 2008-11-13 |
IL201165A0 (en) | 2010-05-17 |
US20090162356A1 (en) | 2009-06-25 |
AU2008247958A1 (en) | 2008-11-13 |
JP2010526076A (ja) | 2010-07-29 |
AR066375A1 (es) | 2009-08-12 |
PE20090239A1 (es) | 2009-03-19 |
RU2009144280A (ru) | 2011-06-10 |
ZA200906812B (en) | 2010-12-29 |
KR20100018523A (ko) | 2010-02-17 |
EP2152749A1 (en) | 2010-02-17 |
CN101675078A (zh) | 2010-03-17 |
MX2009011407A (es) | 2009-11-05 |
WO2008137338A1 (en) | 2008-11-13 |
BRPI0810926A2 (pt) | 2014-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008001238A1 (es) | Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi | |
AR119754A2 (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan | |
CY1120417T1 (el) | Μεθοδοι για τη μειωση των επιπεδων των βασεοφιλων | |
CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
CL2011000269A1 (es) | Anticuerpo o fragmento del mismo que se une a cd127; y metodo de tratamiento de enfermedad autoinmune o un trastorno inflamatorio en humanos, que comprende administrar un antagonista de al menos una de la expansion de th17 mediada por el receptor de il-7 y la supervivencia de th17 mediada por el receptor de il-7. | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
BRPI0510170B8 (pt) | composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto | |
CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
TW201129378A (en) | Materials and methods for treating or preventing HER-3 associated diseases | |
EA201170636A1 (ru) | Антагонисты толл-подобного рецептора 3 | |
EA201290254A1 (ru) | Антагонисты il-17a | |
BRPI0921999B8 (pt) | uso de uma quantidade terapeuticamente eficaz de células tronco placentárias | |
CL2008002228A1 (es) | Compuestos derivados de imidazopiridinonas, agonista de tlr7; procedimiento de preparacion; compuestos intermediarios; composiicon farmaceutica que los comprende; y uso en infecciones virales, bacterianas y fungicas. | |
PE20091193A1 (es) | Proteinas humanas de union a antigenos del gm-csf | |
CL2018000750A1 (es) | Método de redireccionamiento de linfocitos t para el tratamiento de la infección por vih | |
WO2010056898A3 (en) | Rapid expression cloning of human monoclonal antibodies from memory b cells | |
AR044927A1 (es) | Metodos y composiciones para tratar la artritis reumatoidea | |
AR054539A1 (es) | Nuevos anticuerpos anti- madcam | |
CL2008002966A1 (es) | Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros. | |
CO6541613A2 (es) | Combinaciones de un antagonista de los receptores muscarínicos y un agonista del adreno-receptor beta 2 | |
MX2008013600A (es) | Antagonistas del receptor de interleuquina-8. | |
AR059605A1 (es) | Metodos para el uso de anticuerpos contra il-22 humana | |
ES2530428T3 (es) | Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos |